Reports Q1 revenue $1.5B, consensus $1.5B. “Ardent delivered solid first quarter 2025 results that reflect the successful execution of our strategic priorities and put us on track to meet our full-year financial targets,” stated Marty Bonick, President and Chief Executive Officer of Ardent Health (ARDT). “Strong underlying volumes and a heightened flu season drove a 7.6% increase in admissions. Adjusted admissions grew 2.7%, tracking toward the upper end of our 2025 guidance and showing durable demand.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARDT:
- Is ARDT a Buy, Before Earnings?
- Apple, Starbucks upgraded: Wall Street’s top analyst calls
- Ardent Health price target lowered to $18 from $19 at Mizuho
- Ardent Health initiated with a Buy at Guggenheim
- Ardent Health Partners, Inc.: Buy Rating Affirmed on Adjusted Earnings Forecast and Stable Financial Outlook
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue